10 XP 0   0   5  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

HTD (Corcept) Stock Analysis
Buy, Hold or Sell?

Let's analyze Corcept together

I guess you are interested in Corcept Therapeutics Incorporated. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Corcept’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Corcept’s Price Targets

I'm going to help you getting a better view of Corcept Therapeutics Incorporated. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Corcept Therapeutics Incorporated

I send you an email if I find something interesting about Corcept Therapeutics Incorporated.

1. Quick Overview

1.1. Quick analysis of Corcept (30 sec.)










1.2. What can you expect buying and holding a share of Corcept? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€5.07
Expected worth in 1 year
€5.36
How sure are you?
85.7%

+ What do you gain per year?

Total Gains per Share
€0.29
Return On Investment
0.4%

For what price can you sell your share?

Current Price per Share
€66.88
Expected price per share
€63.04 - €105.30
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Corcept (5 min.)




Live pricePrice per Share (EOD)
€66.88
Intrinsic Value Per Share
€18.42 - €21.68
Total Value Per Share
€23.49 - €26.76

2.2. Growth of Corcept (5 min.)




Is Corcept growing?

Current yearPrevious yearGrowGrow %
How rich?$635.8m$528.1m$131.2m19.9%

How much money is Corcept making?

Current yearPrevious yearGrowGrow %
Making money$33.4m$31.4m$1.9m5.7%
Net Profit Margin18.5%22.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Corcept (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#97 / 853

Most Revenue
#60 / 853

Most Profit
#56 / 853
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Corcept?

Welcome investor! Corcept's management wants to use your money to grow the business. In return you get a share of Corcept.

First you should know what it really means to hold a share of Corcept. And how you can make/lose money.

Speculation

The Price per Share of Corcept is €66.88. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Corcept.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Corcept, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €5.07. Based on the TTM, the Book Value Change Per Share is €0.07 per quarter. Based on the YOY, the Book Value Change Per Share is €0.35 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Corcept.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 β‚¬% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share
Usd Eps0.330.5%0.320.5%0.300.4%0.290.4%0.270.4%0.250.4%
Usd Book Value Change Per Share-0.45-0.7%0.080.1%0.410.6%0.150.2%0.100.2%0.170.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.45-0.7%0.080.1%0.410.6%0.150.2%0.100.2%0.170.3%
Usd Price Per Share74.10-75.33-33.60-44.70-35.91-26.52-
Price to Earnings Ratio55.89-72.36-28.16-42.40-35.33-30.51-
Price-to-Total Gains Ratio-164.10--12,800.11-81.36--4,216.28--2,511.60--1,400.12-
Price to Book Ratio12.36-12.01-6.79-8.15-7.06-8.33-
Price-to-Total Gains Ratio-164.10--12,800.11-81.36--4,216.28--2,511.60--1,400.12-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share79.065536
Number of shares12
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.080.10
Usd Total Gains Per Share0.080.10
Gains per Quarter (12 shares)1.011.24
Gains per Year (12 shares)4.044.97
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
104-605-5
208-20100
301220155
4016602010
50201002515
60241403020
70281803525
80322204030
90362604535
100403005040

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%35.00.00.0100.0%35.00.00.0100.0%
Book Value Change Per Share2.02.00.050.0%9.03.00.075.0%15.05.00.075.0%30.05.00.085.7%30.05.00.085.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.035.00.0%0.00.035.00.0%
Total Gains per Share2.02.00.050.0%9.03.00.075.0%15.05.00.075.0%30.05.00.085.7%30.05.00.085.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Corcept Therapeutics Incorporated compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.3820.071-636%0.350-209%0.130-393%0.088-536%0.145-364%
Book Value Per Share--5.0725.277-4%4.240+20%4.438+14%4.093+24%3.137+62%
Current Ratio--3.0633.295-7%4.669-34%4.890-37%6.429-52%6.295-51%
Debt To Asset Ratio--0.2070.194+7%0.184+12%0.175+18%0.143+45%0.149+39%
Debt To Equity Ratio--0.2610.241+8%0.227+15%0.214+22%0.170+53%0.185+41%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--6506522204.1806606447625.945-2%2894794221.450+125%3904562389.025+67%3189168694.260+104%2355041534.186+176%
Eps--0.2800.268+5%0.252+11%0.243+15%0.225+25%0.210+34%
Ev To Sales Ratio--9.89011.244-12%6.095+62%7.830+26%7.441+33%7.132+39%
Free Cash Flow Per Share--0.3500.361-3%0.247+41%0.292+20%0.282+24%0.286+23%
Free Cash Flow To Equity Per Share---0.4710.025-1983%0.236-300%0.161-392%0.087-640%0.111-526%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--21.684----------
Intrinsic Value_10Y_min--18.422----------
Intrinsic Value_1Y_max--1.314----------
Intrinsic Value_1Y_min--1.290----------
Intrinsic Value_3Y_max--4.603----------
Intrinsic Value_3Y_min--4.381----------
Intrinsic Value_5Y_max--8.680----------
Intrinsic Value_5Y_min--8.000----------
Market Cap7047279360.000+6%6646881545.2806740836816.320-1%2994935670.000+122%4006195652.717+66%3266546804.630+103%2410884927.789+176%
Net Profit Margin--0.1810.185-2%0.223-19%0.210-14%0.240-25%0.307-41%
Operating Margin----0%0.063-100%0.065-100%0.168-100%0.246-100%
Operating Ratio--0.8800.878+0%0.789+12%0.816+8%0.767+15%0.683+29%
Pb Ratio13.187+6%12.35912.013+3%6.790+82%8.152+52%7.060+75%8.329+48%
Pe Ratio59.634+6%55.88972.358-23%28.156+98%42.401+32%35.331+58%30.510+83%
Price Per Share66.880+6%62.68063.723-2%28.423+121%37.809+66%30.379+106%22.431+179%
Price To Free Cash Flow Ratio47.766+6%44.766182.263-75%57.022-21%86.625-48%60.110-26%34.926+28%
Price To Total Gains Ratio-175.098-7%-164.102-12800.113+7700%81.363-302%-4216.281+2469%-2511.599+1431%-1400.123+753%
Quick Ratio--2.1022.190-4%3.075-32%3.242-35%4.765-56%4.611-54%
Return On Assets--0.0440.041+6%0.049-10%0.044-1%0.047-7%0.070-37%
Return On Equity--0.0550.051+8%0.060-8%0.054+3%0.055+1%0.083-33%
Total Gains Per Share---0.3820.071-636%0.350-209%0.130-393%0.088-536%0.145-364%
Usd Book Value--635807610.523659390652.449-4%528134886.261+20%556379201.967+14%524465251.935+21%402013638.061+58%
Usd Book Value Change Per Share---0.4520.084-636%0.414-209%0.154-393%0.103-536%0.171-364%
Usd Book Value Per Share--5.9966.239-4%5.012+20%5.246+14%4.838+24%3.708+62%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--7692010549.7827810142383.392-2%3422225728.598+125%4615973656.305+67%3770235230.354+104%2784130101.714+176%
Usd Eps--0.3310.316+5%0.298+11%0.287+15%0.266+25%0.248+34%
Usd Free Cash Flow--43883008.40845070785.703-3%30820958.249+42%36530422.783+20%36170831.187+21%23136703.098+90%
Usd Free Cash Flow Per Share--0.4140.427-3%0.292+41%0.345+20%0.334+24%0.338+23%
Usd Free Cash Flow To Equity Per Share---0.5570.030-1983%0.279-300%0.191-392%0.103-640%0.131-526%
Usd Market Cap8331293659.392+6%7857943362.8307969017284.254-1%3540612949.074+122%4736124500.642+66%3861711632.434+103%2850148161.632+176%
Usd Price Per Share79.066+6%74.10075.333-2%33.601+121%44.698+66%35.914+106%26.517+179%
Usd Profit--35149807.72433414517.848+5%31496473.772+12%29521845.063+19%28230348.719+25%26466208.179+33%
Usd Revenue--194434468.001179024113.880+9%142405772.409+37%142823532.009+36%122450663.852+59%96331213.640+102%
Usd Total Gains Per Share---0.4520.084-636%0.414-209%0.154-393%0.103-536%0.171-364%
 EOD+3 -5MRQTTM+10 -25YOY+17 -193Y+19 -175Y+19 -1710Y+17 -19

3.3 Fundamental Score

Let's check the fundamental score of Corcept Therapeutics Incorporated based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1559.634
Price to Book Ratio (EOD)Between0-113.187
Net Profit Margin (MRQ)Greater than00.181
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.102
Current Ratio (MRQ)Greater than13.063
Debt to Asset Ratio (MRQ)Less than10.207
Debt to Equity Ratio (MRQ)Less than10.261
Return on Equity (MRQ)Greater than0.150.055
Return on Assets (MRQ)Greater than0.050.044
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Corcept Therapeutics Incorporated based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5067.209
Ma 20Greater thanMa 5060.352
Ma 50Greater thanMa 10060.471
Ma 100Greater thanMa 20061.795
OpenGreater thanClose63.260
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Fundamental data was last updated by Penke on 2025-08-19 20:25:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Corcept earns for each €1 of revenue.

  • Above 10% is considered healthy but always compareΒ Corcept to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 18.1%Β means thatΒ €0.18 for each €1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Corcept Therapeutics Incorporated:

  • The MRQ is 18.1%. The company is making a huge profit. +2
  • The TTM is 18.5%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ18.1%TTM18.5%-0.4%
TTM18.5%YOY22.3%-3.8%
TTM18.5%5Y24.0%-5.5%
5Y24.0%10Y30.7%-6.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ18.1%-86.1%+104.2%
TTM18.5%-169.5%+188.0%
YOY22.3%-209.8%+232.1%
3Y21.0%-284.5%+305.5%
5Y24.0%-380.6%+404.6%
10Y30.7%-519.5%+550.2%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Corcept is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Corcept to theΒ Biotechnology industry mean.
  • 4.4% Return on Assets means thatΒ Corcept generatedΒ €0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Corcept Therapeutics Incorporated:

  • The MRQ is 4.4%. Using its assets, the company is less efficient in making profit.
  • The TTM is 4.1%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ4.4%TTM4.1%+0.3%
TTM4.1%YOY4.9%-0.8%
TTM4.1%5Y4.7%-0.6%
5Y4.7%10Y7.0%-2.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.4%-12.1%+16.5%
TTM4.1%-12.0%+16.1%
YOY4.9%-11.2%+16.1%
3Y4.4%-12.0%+16.4%
5Y4.7%-11.7%+16.4%
10Y7.0%-13.8%+20.8%
4.3.1.3. Return on Equity

Shows how efficient Corcept is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Corcept to theΒ Biotechnology industry mean.
  • 5.5% Return on Equity means Corcept generated €0.06Β for eachΒ €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Corcept Therapeutics Incorporated:

  • The MRQ is 5.5%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 5.1%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ5.5%TTM5.1%+0.4%
TTM5.1%YOY6.0%-0.9%
TTM5.1%5Y5.5%-0.4%
5Y5.5%10Y8.3%-2.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.5%-14.3%+19.8%
TTM5.1%-15.2%+20.3%
YOY6.0%-15.2%+21.2%
3Y5.4%-16.8%+22.2%
5Y5.5%-17.5%+23.0%
10Y8.3%-19.6%+27.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Corcept Therapeutics Incorporated.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Corcept is operatingΒ .

  • Measures how much profit Corcept makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Corcept to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated €0.00 Β for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Corcept Therapeutics Incorporated:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY6.3%-6.3%
TTM-5Y16.8%-16.8%
5Y16.8%10Y24.6%-7.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--161.5%+161.5%
TTM--286.7%+286.7%
YOY6.3%-254.3%+260.6%
3Y6.5%-270.1%+276.6%
5Y16.8%-356.3%+373.1%
10Y24.6%-528.7%+553.3%
4.3.2.2. Operating Ratio

Measures how efficient Corcept is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.88 means that the operating costs are €0.88 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Corcept Therapeutics Incorporated:

  • The MRQ is 0.880. The company is less efficient in keeping operating costs low.
  • The TTM is 0.878. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.880TTM0.878+0.003
TTM0.878YOY0.789+0.089
TTM0.8785Y0.767+0.111
5Y0.76710Y0.683+0.084
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8801.929-1.049
TTM0.8782.934-2.056
YOY0.7892.982-2.193
3Y0.8163.799-2.983
5Y0.7674.893-4.126
10Y0.6836.841-6.158
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Corcept Therapeutics Incorporated.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Corcept is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 3.06Β means the company has €3.06 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Corcept Therapeutics Incorporated:

  • The MRQ is 3.063. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.295. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.063TTM3.295-0.231
TTM3.295YOY4.669-1.374
TTM3.2955Y6.429-3.135
5Y6.42910Y6.295+0.134
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0633.480-0.417
TTM3.2953.736-0.441
YOY4.6694.133+0.536
3Y4.8904.591+0.299
5Y6.4295.762+0.667
10Y6.2956.154+0.141
4.4.3.2. Quick Ratio

Measures if Corcept is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Corcept to theΒ Biotechnology industry mean.
  • A Quick Ratio of 2.10Β means the company can pay off €2.10 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Corcept Therapeutics Incorporated:

  • The MRQ is 2.102. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.190. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.102TTM2.190-0.088
TTM2.190YOY3.075-0.885
TTM2.1905Y4.765-2.575
5Y4.76510Y4.611+0.154
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1022.930-0.828
TTM2.1903.192-1.002
YOY3.0753.990-0.915
3Y3.2424.381-1.139
5Y4.7655.837-1.072
10Y4.6116.540-1.929
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Corcept Therapeutics Incorporated.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of CorceptΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Corcept to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.21Β means that Corcept assets areΒ financed with 20.7% credit (debt) and the remaining percentage (100% - 20.7%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Corcept Therapeutics Incorporated:

  • The MRQ is 0.207. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.194. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.207TTM0.194+0.013
TTM0.194YOY0.184+0.010
TTM0.1945Y0.143+0.051
5Y0.14310Y0.149-0.006
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2070.339-0.132
TTM0.1940.359-0.165
YOY0.1840.334-0.150
3Y0.1750.341-0.166
5Y0.1430.349-0.206
10Y0.1490.379-0.230
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Corcept is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Corcept to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 26.1% means that company has €0.26 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Corcept Therapeutics Incorporated:

  • The MRQ is 0.261. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.241. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.261TTM0.241+0.020
TTM0.241YOY0.227+0.014
TTM0.2415Y0.170+0.071
5Y0.17010Y0.185-0.015
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2610.391-0.130
TTM0.2410.432-0.191
YOY0.2270.427-0.200
3Y0.2140.462-0.248
5Y0.1700.459-0.289
10Y0.1850.514-0.329
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every €1 in earnings Corcept generates.

  • Above 15 is considered overpriced butΒ always compareΒ Corcept to theΒ Biotechnology industry mean.
  • A PE ratio of 55.89 means the investor is paying €55.89Β for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Corcept Therapeutics Incorporated:

  • The EOD is 59.634. Based on the earnings, the company is expensive. -2
  • The MRQ is 55.889. Based on the earnings, the company is expensive. -2
  • The TTM is 72.358. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD59.634MRQ55.889+3.745
MRQ55.889TTM72.358-16.469
TTM72.358YOY28.156+44.202
TTM72.3585Y35.331+37.027
5Y35.33110Y30.510+4.821
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD59.634-2.542+62.176
MRQ55.889-2.355+58.244
TTM72.358-2.660+75.018
YOY28.156-3.770+31.926
3Y42.401-3.843+46.244
5Y35.331-6.412+41.743
10Y30.510-7.084+37.594
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Corcept Therapeutics Incorporated:

  • The EOD is 47.766. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 44.766. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 182.263. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD47.766MRQ44.766+3.000
MRQ44.766TTM182.263-137.496
TTM182.263YOY57.022+125.241
TTM182.2635Y60.110+122.152
5Y60.11010Y34.926+25.184
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD47.766-3.327+51.093
MRQ44.766-3.016+47.782
TTM182.263-3.645+185.908
YOY57.022-4.377+61.399
3Y86.625-5.257+91.882
5Y60.110-8.487+68.597
10Y34.926-9.626+44.552
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Corcept is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 12.36 means the investor is paying €12.36Β for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Corcept Therapeutics Incorporated:

  • The EOD is 13.187. Based on the equity, the company is expensive. -2
  • The MRQ is 12.359. Based on the equity, the company is expensive. -2
  • The TTM is 12.013. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD13.187MRQ12.359+0.828
MRQ12.359TTM12.013+0.346
TTM12.013YOY6.790+5.223
TTM12.0135Y7.060+4.953
5Y7.06010Y8.329-1.270
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD13.1872.201+10.986
MRQ12.3592.007+10.352
TTM12.0132.189+9.824
YOY6.7902.409+4.381
3Y8.1522.558+5.594
5Y7.0603.764+3.296
10Y8.3294.462+3.867
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets801,722
Total Liabilities165,929
Total Stockholder Equity635,793
 As reported
Total Liabilities 165,929
Total Stockholder Equity+ 635,793
Total Assets = 801,722

Assets

Total Assets801,722
Total Current Assets443,112
Long-term Assets358,610
Total Current Assets
Cash And Cash Equivalents 102,745
Short-term Investments 239,481
Net Receivables 64,567
Inventory 12,276
Other Current Assets 7,470
Total Current Assets  (as reported)443,112
Total Current Assets  (calculated)426,539
+/- 16,573
Long-term Assets
Property Plant Equipment 7,312
Long Term Investments 172,775
Long-term Assets Other 16,294
Long-term Assets  (as reported)358,610
Long-term Assets  (calculated)196,381
+/- 162,229

Liabilities & Shareholders' Equity

Total Current Liabilities144,664
Long-term Liabilities21,265
Total Stockholder Equity635,793
Total Current Liabilities
Accounts payable 23,525
Other Current Liabilities 6,884
Total Current Liabilities  (as reported)144,664
Total Current Liabilities  (calculated)30,409
+/- 114,255
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt6,605
Long-term Liabilities  (as reported)21,265
Long-term Liabilities  (calculated)6,605
+/- 14,660
Total Stockholder Equity
Retained Earnings 599,431
Total Stockholder Equity (as reported)635,793
Total Stockholder Equity (calculated)599,431
+/- 36,362
Other
Capital Stock138
Common Stock Shares Outstanding 106,045
Net Invested Capital 635,793
Net Working Capital 298,448
Property Plant and Equipment Gross 7,312



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
68,753
75,339
86,537
110,672
220,537
242,976
274,382
299,751
311,694
320,212
328,679
367,022
412,312
445,494
497,823
534,125
571,731
552,398
568,480
585,399
423,756
468,123
496,364
533,255
583,430
617,848
524,625
594,022
621,517
655,935
714,555
784,257
840,553
846,455
801,722
801,722846,455840,553784,257714,555655,935621,517594,022524,625617,848583,430533,255496,364468,123423,756585,399568,480552,398571,731534,125497,823445,494412,312367,022328,679320,212311,694299,751274,382242,976220,537110,67286,53775,33968,753
   > Total Current Assets 
65,689
66,675
81,285
93,942
124,185
150,823
197,175
224,191
236,820
216,864
232,655
267,310
307,358
344,776
438,333
463,493
478,501
409,624
411,270
401,900
266,463
388,220
419,045
452,402
499,253
533,893
432,588
431,527
458,636
503,367
560,846
466,978
471,602
438,503
443,112
443,112438,503471,602466,978560,846503,367458,636431,527432,588533,893499,253452,402419,045388,220266,463401,900411,270409,624478,501463,493438,333344,776307,358267,310232,655216,864236,820224,191197,175150,823124,18593,94281,28566,67565,689
       Cash And Cash Equivalents 
51,536
37,976
33,623
31,060
31,062
33,121
31,165
33,894
41,625
49,650
58,141
44,948
31,269
84,477
58,523
30,560
76,190
52,381
95,430
94,688
77,617
61,862
35,346
50,243
436,619
299,942
172,377
111,800
135,551
149,750
128,588
137,289
127,665
89,819
102,745
102,74589,819127,665137,289128,588149,750135,551111,800172,377299,942436,61950,24335,34661,86277,61794,68895,43052,38176,19030,56058,52384,47731,26944,94858,14149,65041,62533,89431,16533,12131,06231,06033,62337,97651,536
       Short-term Investments 
0
14,798
32,542
44,096
57,682
92,241
128,780
161,300
165,135
137,255
143,396
186,697
244,693
222,838
346,835
398,233
364,506
320,578
274,552
266,643
145,918
283,665
334,740
346,019
365,343
165,115
190,885
243,425
232,670
261,011
344,568
243,047
255,669
232,944
239,481
239,481232,944255,669243,047344,568261,011232,670243,425190,885165,115365,343346,019334,740283,665145,918266,643274,552320,578364,506398,233346,835222,838244,693186,697143,396137,255165,135161,300128,78092,24157,68244,09632,54214,7980
       Net Receivables 
9,860
9,214
9,504
11,872
15,300
17,261
28,704
19,360
17,588
19,218
19,774
22,405
19,928
26,684
22,725
25,357
27,498
23,900
29,020
27,908
29,025
28,178
29,864
30,314
46,857
32,557
47,153
49,926
41,123
61,518
53,837
59,717
53,976
61,819
64,567
64,56761,81953,97659,71753,83761,51841,12349,92647,15332,55746,85730,31429,86428,17829,02527,90829,02023,90027,49825,35722,72526,68419,92822,40519,77419,21817,58819,36028,70417,26115,30011,8729,5049,2149,860
       Inventory 
2,329
2,888
3,089
3,828
4,576
4,876
4,947
5,362
4,732
5,000
5,142
5,462
5,424
5,084
4,927
4,817
4,910
4,948
4,669
4,994
4,988
5,079
5,437
6,046
6,100
6,409
6,915
7,513
7,730
7,190
8,350
8,050
12,412
14,368
12,276
12,27614,36812,4128,0508,3507,1907,7307,5136,9156,4096,1006,0465,4375,0794,9884,9944,6694,9484,9104,8174,9275,0845,4245,4625,1425,0004,7325,3624,9474,8764,5763,8283,0892,8882,329
       Other Current Assets 
1,964
1,799
2,527
3,086
12,896
3,324
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16,424
15,870
15,858
20,163
5,882
18,356
9,126
4,580
6,078
24,866
7,470
7,47024,8666,0784,5809,12618,3565,88220,16315,85815,87016,4240000000000000000003,32412,8963,0862,5271,7991,964
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
103,348
96,024
99,712
104,954
100,718
59,490
70,632
93,230
142,774
157,210
183,499
157,293
79,903
77,319
80,853
84,723
83,955
92,037
162,495
162,881
152,568
153,709
317,279
368,951
407,952
358,610
358,610407,952368,951317,279153,709152,568162,881162,49592,03783,95584,72380,85377,31979,903157,293183,499157,210142,77493,23070,63259,490100,718104,95499,71296,024103,348000000000
       Property Plant Equipment 
3,040
4,122
499
553
518
577
552
540
655
2,390
2,283
1,969
4,496
3,962
4,091
4,304
4,184
3,501
2,938
2,248
1,516
3,542
3,126
2,508
1,143
1,036
648
480
315
188
7,156
8,433
8,013
7,690
7,312
7,3127,6908,0138,4337,1561883154806481,0361,1432,5083,1263,5421,5162,2482,9383,5014,1844,3044,0913,9624,4961,9692,2832,3906555405525775185534994,1223,040
       Long Term Investments 
0
4,493
1,494
1,508
15,281
15,010
0
1,481
0
28,842
24,165
35,250
39,352
41,690
4,200
15,425
36,196
81,834
101,657
133,845
112,277
22,566
11,890
4,895
4,947
0
0
59,621
57,176
40,276
19,315
167,310
219,831
248,041
172,775
172,775248,041219,831167,31019,31540,27657,17659,621004,9474,89511,89022,566112,277133,845101,65781,83436,19615,4254,20041,69039,35235,25024,16528,84201,481015,01015,2811,5081,4944,4930
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
10,435
12,876
11,689
15,429
14,504
15,729
17,085
21,247
20,414
18,874
17,765
16,045
16,082
13,812
16,108
22,115
14,920
13,175
15,292
14,785
14,234
15,390
14,737
10,193
7,776
16,294
16,2947,77610,19314,73715,39014,23414,78515,29213,17514,92022,11516,10813,81216,08216,04517,76518,87420,41421,24717,08515,72914,50415,42911,68912,87610,435000000000
> Total Liabilities 
27,374
25,759
20,392
24,370
29,569
27,749
30,873
40,206
35,812
34,457
30,626
32,646
41,130
36,005
44,125
44,445
48,393
41,596
45,805
45,170
47,950
60,312
54,038
59,891
81,588
88,264
103,011
132,343
114,812
108,071
118,312
145,422
160,964
163,170
165,929
165,929163,170160,964145,422118,312108,071114,812132,343103,01188,26481,58859,89154,03860,31247,95045,17045,80541,59648,39344,44544,12536,00541,13032,64630,62634,45735,81240,20630,87327,74929,56924,37020,39225,75927,374
   > Total Current Liabilities 
27,374
25,759
20,392
24,370
29,569
27,749
30,873
40,206
35,573
34,218
30,381
32,396
38,841
34,075
42,243
43,048
47,494
40,601
45,402
44,757
47,541
57,244
49,057
53,068
72,491
78,865
93,059
121,873
104,505
97,202
100,750
126,216
140,773
143,066
144,664
144,664143,066140,773126,216100,75097,202104,505121,87393,05978,86572,49153,06849,05757,24447,54144,75745,40240,60147,49443,04842,24334,07538,84132,39630,38134,21835,57340,20630,87327,74929,56924,37020,39225,75927,374
       Short-term Debt 
14,664
10,107
4,573
0
0
0
0
0
0
1,521
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000001,5210000004,57310,10714,664
       Short Long Term Debt 
14,664
10,107
4,573
0
0
0
0
0
0
1,521
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000001,5210000004,57310,10714,664
       Accounts payable 
12,710
15,652
2,082
6,226
8,579
7,850
6,365
13,922
8,266
9,330
7,026
5,937
7,537
4,976
6,304
6,510
10,554
6,969
9,216
6,558
6,908
9,269
8,246
8,178
11,976
11,216
7,976
16,710
17,396
12,557
19,484
18,584
15,376
27,947
23,525
23,52527,94715,37618,58419,48412,55717,39616,7107,97611,21611,9768,1788,2469,2696,9086,5589,2166,96910,5546,5106,3044,9767,5375,9377,0269,3308,26613,9226,3657,8508,5796,2262,08215,65212,710
       Other Current Liabilities 
0
0
0
0
20,990
728
687
1,583
1,542
450
469
552
751
4,473
5,698
249
202
314
977
518
809
12,000
623
863
872
1,220
34,126
44,960
654
0
5,296
7,302
2,272
4,026
6,884
6,8844,0262,2727,3025,296065444,96034,1261,22087286362312,0008095189773142022495,6984,4737515524694501,5421,58368772820,9900000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
239
245
250
2,289
1,930
1,882
1,397
899
995
403
413
409
3,068
4,981
6,823
9,097
9,399
9,952
10,470
10,307
10,869
17,562
19,206
20,191
20,104
21,265
21,26520,10420,19119,20617,56210,86910,30710,4709,9529,3999,0976,8234,9813,0684094134039958991,3971,8821,9302,289250245239000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
239
239
245
250
386
389
396
400
398
995
403
413
409
2,516
4,981
6,823
9,097
0
0
10,470
0
0
0
0
0
0
0
000000010,470009,0976,8234,9812,51640941340399539840039638938625024523923900000000
> Total Stockholder Equity
41,379
49,580
66,145
86,302
190,968
215,227
243,509
259,545
275,882
285,755
298,053
334,376
371,182
409,489
453,698
489,680
523,338
510,802
522,675
540,229
375,806
407,811
442,326
473,364
501,842
529,584
421,614
461,679
506,705
547,864
596,243
638,835
679,589
683,285
635,793
635,793683,285679,589638,835596,243547,864506,705461,679421,614529,584501,842473,364442,326407,811375,806540,229522,675510,802523,338489,680453,698409,489371,182334,376298,053285,755275,882259,545243,509215,227190,96886,30266,14549,58041,379
   Common Stock
113
113
113
114
115
115
116
116
117
118
118
119
120
120
121
121
122
124
125
126
127
128
128
130
131
0
0
133
0
0
0
0
0
0
0
000000013300131130128128127126125124122121121120120119118118117116116115115114113113113
   Retained Earnings Total Equity00000000000000000000000000000000000
   Accumulated Other Comprehensive Income 00000000000000000000000000000000000
   Capital Surplus 00000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000
   Other Stockholders Equity 
0
-12
-17
-14
-75
-152
-127
-77
-70
94
321
314
261
310
840
577
415
249
215
115
-227
-1,351
-2,141
-2,381
-869
0
0
-234
0
0
0
0
0
0
0
0000000-23400-869-2,381-2,141-1,351-22711521524941557784031026131432194-70-77-127-152-75-14-17-120



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue675,040
Cost of Revenue-10,882
Gross Profit664,158664,158
 
Operating Income (+$)
Gross Profit664,158
Operating Expense-538,089
Operating Income136,951126,069
 
Operating Expense (+$)
Research Development246,887
Selling General Administrative280,320
Selling And Marketing Expenses-
Operating Expense538,089527,207
 
Net Interest Income (+$)
Interest Income24,542
Interest Expense--
Other Finance Cost-0
Net Interest Income24,542
 
Pretax Income (+$)
Operating Income136,951
Net Interest Income24,542
Other Non-Operating Income Expenses-
Income Before Tax (EBT)161,493136,951
EBIT - interestExpense = 0
141,209
141,209
Interest Expense-
Earnings Before Interest and Taxes (EBIT)-161,493
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax161,493
Tax Provision-20,284
Net Income From Continuing Ops141,209141,209
Net Income141,209
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--24,542
 

Technical Analysis of Corcept
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Corcept. The general trend of Corcept is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Corcept's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Corcept Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Corcept Therapeutics Incorporated.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 72.28 < 105.30.

The bearish price targets are: 65.60 > 63.64 > 63.04.

Know someone who trades $HTD? Share this with them.πŸ‘‡

Corcept Therapeutics Incorporated Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Corcept Therapeutics Incorporated. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Corcept Therapeutics Incorporated Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Corcept Therapeutics Incorporated. The current macd is 0.46608984.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Corcept price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Corcept. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Corcept price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Corcept Therapeutics Incorporated Daily Moving Average Convergence/Divergence (MACD) ChartCorcept Therapeutics Incorporated Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Corcept Therapeutics Incorporated. The current adx is 14.83.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Corcept shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Corcept Therapeutics Incorporated Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Corcept Therapeutics Incorporated. The current sar is 58.24.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Corcept Therapeutics Incorporated Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Corcept Therapeutics Incorporated. The current rsi is 67.21. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Corcept Therapeutics Incorporated Daily Relative Strength Index (RSI) ChartCorcept Therapeutics Incorporated Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Corcept Therapeutics Incorporated. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Corcept price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Corcept Therapeutics Incorporated Daily Stochastic Oscillator ChartCorcept Therapeutics Incorporated Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Corcept Therapeutics Incorporated. The current cci is 358.81.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Corcept Therapeutics Incorporated Daily Commodity Channel Index (CCI) ChartCorcept Therapeutics Incorporated Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Corcept Therapeutics Incorporated. The current cmo is 45.98.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Corcept Therapeutics Incorporated Daily Chande Momentum Oscillator (CMO) ChartCorcept Therapeutics Incorporated Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Corcept Therapeutics Incorporated. The current willr is 0.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Corcept Therapeutics Incorporated Daily Williams %R ChartCorcept Therapeutics Incorporated Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Corcept Therapeutics Incorporated.

Corcept Therapeutics Incorporated Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Corcept Therapeutics Incorporated. The current atr is 1.59988376.

Corcept Therapeutics Incorporated Daily Average True Range (ATR) ChartCorcept Therapeutics Incorporated Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Corcept Therapeutics Incorporated. The current obv is -1,181.

Corcept Therapeutics Incorporated Daily On-Balance Volume (OBV) ChartCorcept Therapeutics Incorporated Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Corcept Therapeutics Incorporated. The current mfi is 63.46.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Corcept Therapeutics Incorporated Daily Money Flow Index (MFI) ChartCorcept Therapeutics Incorporated Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Corcept Therapeutics Incorporated.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-05-06 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-08 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-09 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-12 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-13 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-14 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-15 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-16 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-19 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-20 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-21 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-22 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-23 00:00:00BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-26 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-30 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-02 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-03 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-04 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-05 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-09 00:00:00MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-06-10 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-06-11 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-12 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-13 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-06-16 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-17 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-06-19 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-20 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-24 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-25 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-26 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-27 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-30 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-01 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-02 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-03 00:00:00MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-07-04 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-07 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-09 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-10 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-14 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-07-17 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-21 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-23 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-25 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-28 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-30 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-31 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-01 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-04 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-06 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-07 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-12 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-08-13 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-18 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-21 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-22 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-26 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-27 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-08-28 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-29 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-09-02 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-03 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-09-04 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-05 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-08 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-09 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-09-10 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-11 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-12 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-15 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-16 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-09-17 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-18 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Corcept Therapeutics Incorporated Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Corcept Therapeutics Incorporated based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5067.209
Ma 20Greater thanMa 5060.352
Ma 50Greater thanMa 10060.471
Ma 100Greater thanMa 20061.795
OpenGreater thanClose63.260
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Corcept with someone you think should read this too:
  • Are you bullish or bearish on Corcept? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Corcept? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Corcept Therapeutics Incorporated

I send you an email if I find something interesting about Corcept Therapeutics Incorporated.


Comments

How you think about this?

Leave a comment

Stay informed about Corcept Therapeutics Incorporated.

Receive notifications about Corcept Therapeutics Incorporated in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.